319
Views
3
CrossRef citations to date
0
Altmetric
Original Articles

Prognostic value of presalvage metabolic tumor volume in patients with relapsed/refractory diffuse large B-cell lymphoma

, , , , , , , , , & show all
Pages 43-53 | Received 13 Jun 2021, Accepted 02 Aug 2021, Published online: 20 Aug 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Adrian Minson, Michael Hofman & Michael Dickinson. (2022) A PET in a time of need: toward early PET-adapted therapy in DLBCL in first relapse. Leukemia & Lymphoma 63:1, pages 1-4.
Read now

Articles from other publishers (2)

Belinda A. Campbell, Rachel Brown, Alessandro Lambertini, Michael S. Hofman, Mathias Bressel, John F. Seymour, Andrew Wirth, Michael MacManus & Michael Dickinson. (2023) Are dynamic or fixed FDG‐PET measures of disease of greater prognostic value in patients with relapsed/refractory diffuse large B‐cell lymphoma undergoing autologous haematopoietic stem cell transplantation?. British Journal of Haematology 201:3, pages 502-509.
Crossref
Russ A. Kuker, David Lehmkuhl, Deukwoo Kwon, Weizhao Zhao, Izidore S. Lossos, Craig H. Moskowitz, Juan Pablo Alderuccio & Fei Yang. (2022) A Deep Learning-Aided Automated Method for Calculating Metabolic Tumor Volume in Diffuse Large B-Cell Lymphoma. Cancers 14:21, pages 5221.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.